The safety of levofloxacin has been well documented, and compared to other respiratory fluoroquinolones has been shown to be associated with a lower incidence of adverse events. The incidence of gastrointestinal, central nervous system and skin reactions were all lower for levofloxacin than for moxifloxacin, gatifloxacin and grepafloxacin.